VIVENS ULYSSE: Open Payments
NPI 1487332615 · WALPOLE, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,034 in 51 payments from 12 companies in 2025. Trend: 2023 $530 · 2024 $1,160 · 2025 $1,034
Food & beverage: $925Education: $109
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 17 | $213 |
| Otsuka America Pharmaceutical, Inc. | 8 | $142 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $119 |
| Teva Pharmaceuticals USA, Inc. | 4 | $117 |
| Alkermes, Inc. | 4 | $94 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| E.R. Squibb & Sons, L.L.C. | 3 | $73 |
| Janssen Pharmaceuticals, Inc | 2 | $65 |
| Lundbeck LLC | 2 | $48 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
Products named: FANAPT, REXULTI, CAPLYTA, AUSTEDO XR, COBENFY, SPRAVATO, Auvelity, ARISTADA.
Industry payments across MA — which companies pay providers there.
